Table 5.
Comparison of outcomes of following active surveillance or immediate radical prostatectomy. Outcomes are based on 1 million simulated patients.
| Immediate RP | Active surveillance | |||
|---|---|---|---|---|
| Treated | 100.00% | 63.68% | ||
| Treated with Gleason score ≤ 6 | 100.00% | 40.69% | ||
| Treated with Gleason score 7 | 0.00% | 19.76% | ||
| Treated with Gleason score ≥ 8 | 0.00% | 3.23% | ||
|
| ||||
| Time to treatment | ||||
| ≤ 3 years | – | 27.75% | ||
| > 3 years | – | 35.93% | ||
|
| ||||
| PSA at treatment (ng/mL) | ||||
| 0–2.5 | 14.43% | 14.55% | ||
| 2.51–4.0 | 14.05% | 13.73% | ||
| 4.1–6.0 | 43.23% | 30.09% | ||
| 6.1–10.0 | 28.29% | 30.42% | ||
| > 10.0 | 0.00% | 11.21% | ||
|
| ||||
| Cumulative incidence of recurrence from diagnosis | ||||
| 20-year | 24.54% | 31.13% | ||
| Lifetime | 29.38% | 37.61% | ||
|
| ||||
| Cumulative incidence of prostate cancer death | ||||
| 20-year | 1.64% | 2.78% | ||
| Lifetime | 2.00% | 3.40% | ||
|
| ||||
| Cumulative incidence of other cause death | ||||
| 20-year | 51.60% | 51.13% | ||
| Lifetime | 98.00% | 96.60% | ||
|
| ||||
| Years of life per person from treatment | 19.66 | 13.30 | ||
| Total years of life per person from diagnosis | 19.66 | 19.50 | ||
| Years of life per person lost due to prostate cancer | 0.25 | 0.40 | ||